{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:15:50Z","timestamp":1792696550473,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40265-013-0152-x","type":"journal-article","created":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T20:15:44Z","timestamp":1384805744000},"page":"1977-1983","source":"Crossref","is-referenced-by-count":33,"title":["Efinaconazole: First Global Approval"],"prefix":"10.1007","volume":"73","author":[{"given":"Trina","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,19]]},"reference":[{"issue":"2","key":"152_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/13543784.16.2.157","volume":"16","author":"MR Alley","year":"2007","unstructured":"Alley MR, Baker SJ, Beutner KR, et al. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs. 2007;16(2):157\u201367.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1\u20132","key":"152_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10354-012-0139-3","volume":"163","author":"G Tchernev","year":"2013","unstructured":"Tchernev G, Penev PK, Nenoff P, et al. Onychomycosis: modern diagnostic and treatment approaches. Wien Med Wochenschr. 2013;163(1\u20132):1\u201312.","journal-title":"Wien Med Wochenschr"},{"issue":"5","key":"152_CR3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clindermatol.2013.06.011","volume":"31","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31(5):544\u201354.","journal-title":"Clin Dermatol."},{"issue":"9","key":"152_CR4","first-page":"1010","volume":"12","author":"M Jarratt","year":"2013","unstructured":"Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10\u00a0% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol. 2013;12(9):1010\u20136.","journal-title":"J Drugs Dermatol."},{"issue":"6","key":"152_CR5","first-page":"305","volume":"91","author":"P Rich","year":"2013","unstructured":"Rich P. Topical treatment of onychomycosis with efinaconazole solution 10\u00a0%. Cutis. 2013;91(6):305\u20137.","journal-title":"Cutis."},{"key":"152_CR6","unstructured":"Valeant Pharmaceuticals International Inc. Valeant Pharmaceuticals announces approval of Jublia\u00ae for the treatment of onychomycosis in Canada [media release]. 3 Oct 2013. http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Approval-Of-Jublia-For-The-Treatment-Of-Onychomycosis-In-Canada\/default.aspx ."},{"key":"152_CR7","unstructured":"Valeant Pharmaceuticals International Inc. Valeant pharmaceuticals announces receipt of U.S. FDA complete response letter for efinaconazole [media release]. 28 May 2013. http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Receipt-Of-US-FDA-Complete-Response-Letter-For-Efinaconazole ."},{"key":"152_CR8","unstructured":"Kaken Pharmaceutical Co. Ltd. R&D pipeline. 2013. http:\/\/www.kaken.co.jp\/english\/rd_pipeline.html . Accessed 22 Oct 2013."},{"key":"152_CR9","unstructured":"Valeant Pharmaceuticals International Inc. Valeant pharmaceuticals provides efinconazole update [media release]. 2 May 2013. http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Provides-Efinconazole-Update\/default.aspx ."},{"key":"152_CR10","unstructured":"Valeant Pharmaceuticals International Inc. Valeant pharmaceuticals announces award in Anacor dispute [media release]. 18 Oct 2013. http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Award-In-Anacor-Dispute\/default.aspx ."},{"key":"152_CR11","unstructured":"Valeant Pharmaceuticals Inc. Valeant Pharmaceuticals announces settlement agreement with Anacor [media release]. 28 Oct 2013. http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2013\/Valeant-Pharmaceuticals-Announces-Settlement-Agreement-With-Anacor\/default.aspx ."},{"key":"152_CR12","unstructured":"Kaken P. Kaken pharmaceutical to license its antifungal compound KP-103 to Dow Pharmaceutical Sciences [media release]. 11 May 2006. http:\/\/www.japancorp.net\/article.asp?Art_ID=12471 ."},{"key":"152_CR13","unstructured":"Valeant Pharmaceuticals International Inc. Valeant Pharmaceuticals completes acquisition of Dow Pharmaceutical Sciences Inc [media release]. 2 Jan 2009. http:\/\/ir.valeant.com\/investor-relations\/news-releases\/news-release-details\/2009\/Valeant-Pharmaceuticals-Completes-Acquisition-of-Dow-Pharmaceutical-Sciences-Inc\/default.aspx ."},{"issue":"5","key":"152_CR14","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.02063-12","volume":"57","author":"Y Tatsumi","year":"2013","unstructured":"Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013;57(5):2405\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4 Suppl 1","key":"152_CR15","first-page":"AB104","volume":"68","author":"V Bhatt","year":"2013","unstructured":"Bhatt V, Sarpotdar P, Pillai R, et al. Development of an optimal formulation for efinaconazole a novel antifungal agent for the treatment of onychomycosis by topical application [abstract no. P6541]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB104.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"152_CR16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.45.5.1493-1499.2001","volume":"45","author":"Y Tatsumi","year":"2001","unstructured":"Tatsumi Y, Yokoo M, Arika T. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother. 2001;45(5):1493\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"152_CR17","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/AAC.46.12.3797-3801.2002","volume":"46","author":"Y Tatsumi","year":"2002","unstructured":"Tatsumi Y, Yokoo M, Senda H. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother. 2002;46(12):3797\u2013801.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"152_CR18","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.02056-12","volume":"57","author":"WJ Jo Siu","year":"2013","unstructured":"Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"Suppl 1","key":"152_CR19","first-page":"S195","volume":"133","author":"K Sugiura","year":"2013","unstructured":"Sugiura K, Hosaka S, Sugimoto N, et al. Efinaconazole\u2019s nail penetration and fungicidal activity may contribute to its therapeutic efficacy as a topical treatment for onychomycosis [abstract no. 1151]. J Invest Dermatol. 2013;133(Suppl 1):S195.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"152_CR20","first-page":"20","volume":"6","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Reece B, Smith K, et al. Efinaconazole 10\u00a0% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. J Clin Aesthet Dermatol. 2013;6(3):20\u20134.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4 Suppl 1","key":"152_CR21","first-page":"AB105","volume":"68","author":"M Glynn","year":"2013","unstructured":"Glynn M, Nejishima H, Sanada H, et al. Efinaconazole 10\u00a0% solution: nonclinical safety supports topical use in onychomycosis [abstract no. P6552]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB105.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"152_CR22","first-page":"82","volume":"32","author":"W Jo","year":"2013","unstructured":"Jo W, Glynn M, Minowa K, et al. Efinaconazole: developmental and reproductive toxicity potential [abstract no. P712]. Int J Toxicol. 2013;32(1):82\u20133.","journal-title":"Int J Toxicol."},{"key":"152_CR23","unstructured":"Jo Siu W, Mutter L, Aoyama A, et al. In vitro CYP inhibition and induction assessments of efinaconazole coupled with low clinical systemic exposure suggest low DDI potential in topical onychomycosis [abstract no. 1140]. J Invest Dermatol. 2013;133 Suppl 1:S193."},{"issue":"4","key":"152_CR24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","volume":"68","author":"BE Elewski","year":"2013","unstructured":"Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10\u00a0% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600\u20138.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"152_CR25","first-page":"186","volume":"12","author":"EH Tschen","year":"2013","unstructured":"Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol. 2013;12(2):186\u201392.","journal-title":"J Drugs Dermatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0152-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0152-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0152-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:34Z","timestamp":1559490094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0152-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":25,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0152-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}